{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T06:33:25Z","timestamp":1792218805397,"version":"4.4.0"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T00:00:00Z","timestamp":1717718400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Yunnan, a southwest highland and newly industrialized region of China, has an unknown hospitalization burden of inflammatory bowel disease (IBD). The study was conducted to explore territorial hospitalization burden of IBD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The formatted medical records of patients with IBD were collected from a territory-wide database in Yunnan Province, China, from 2015 to 2020. General characteristics of the study population were reported using descriptive statistics. To evaluate the length of stay, hospitalization costs, surgery, complications, and trends in patients with inflammatory bowel disease. The logistic regression analysis was established to explore the factors affecting the hospitalization costs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 12,174 records from 8192 patients were included. The annual hospitalization cost of IBD in Yunnan Province increased significantly from 2015 to 2020. From 2015 to 2020, the regional hospitalization burden of IBD increased, but it represented a decline in cost per hospitalization (<jats:italic>r<\/jats:italic> = \u22120.024, <jats:italic>P<\/jats:italic> = 0.008) and the length of stay (<jats:italic>r<\/jats:italic> = \u22120.098, <jats:italic>P<\/jats:italic> &amp;lt; 0.001). Surgery rates for hospitalized patients with Crohn\u2019s disease (CD) did not decrease (<jats:italic>r<\/jats:italic> = \u22120.002, <jats:italic>P<\/jats:italic> = 0.932), and even increased for patients with ulcerative colitis (UC) (<jats:italic>r<\/jats:italic> = 0.03, <jats:italic>P<\/jats:italic> = 0.002). The costs per hospitalization were $ 827.49 (540.11\u20131295.50) for UC and $ 1057.03 (644.26\u20131888.78) for CD. Among the identifiable cost items during the period, drug costs accounted for the highest proportion, accounting for 33% and 37.30% in patients with UC and CD, respectively. Surgical intervention [OR 4.87 (3.75\u20136.31), <jats:italic>P<\/jats:italic> &amp;lt; 0.001], comorbidities [OR 1.72 (1.52\u20131.94), <jats:italic>P<\/jats:italic> &amp;lt; 0.001], complications [OR 1.53 (1.32\u20131.78), <jats:italic>P<\/jats:italic> &amp;lt; 0.001], and endoscopy [OR 2.06 (1.86\u20132.28), <jats:italic>P<\/jats:italic> &amp;lt; 0.001] were predictor of high hospitalization costs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The increasing burden of IBD is noteworthy a newly industrialized region of China. Interventions targeting surgery, complications, and comorbidities may be effective means of controlling the increasing hospitalization costs of IBD in the regions.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2024.1410714","type":"journal-article","created":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T19:15:48Z","timestamp":1718133348000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["The hospitalization burden of inflammatory bowel disease in a southwestern highland region of China: a territory-wide study from 2015 to 2020"],"prefix":"10.3389","volume":"11","author":[{"given":"Yan","family":"Tao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maojuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huabin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengrui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junkun","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinglei","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,6,7]]},"reference":[{"key":"B1","first-page":"S76","article-title":"[Epidemiology and natural history of chronic inflammatory bowel disease].","volume":"27","author":"Lerebours","year":"2003","journal-title":"Gastroenterol Clin Biol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41575-022-00593-y","article-title":"Multiomics to elucidate inflammatory bowel disease risk factors and pathways.","volume":"19","author":"Agrawal","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/nrgastro.2015.150","article-title":"The global burden of IBD: From 2015 to 2025.","volume":"12","author":"Kaplan","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.sapharm.2016.05.042","article-title":"An evaluation of health care expenditures in Crohn\u2019s disease using the United States medical expendit ure panel survey from 2003 to 2013.","volume":"13","author":"Bounthavong","year":"2017","journal-title":"Res Social Adm Pharm."},{"key":"B5","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1097\/MOG.0000000000000642","article-title":"The burden of cost in inflammatory bowel disease: A medical economic perspective.","volume":"36","author":"Beard","year":"2020","journal-title":"Curr Opin Gastroenterol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/S2468-1253(19)30358-9","article-title":"Global burden of inflammatory bowel disease.","volume":"5","author":"Jairath","year":"2020","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/S2468-1253(19)30173-6","article-title":"Comorbidities in inflammatory bowel disease: A call for action.","volume":"4","author":"Argollo","year":"2019","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"B8","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2468-1253(19)30333-4","article-title":"The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: A systematic analysis for the global burden of disease study 2017.","volume":"5","year":"2020","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies.","volume":"390","author":"Ng","year":"2017","journal-title":"Lancet."},{"key":"B10","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41575-020-00360-x","article-title":"The four epidemiological stages in the global evolution of inflammatory bowel disease.","volume":"18","author":"Kaplan","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2012-303383","article-title":"Role of biological therapy for inflammatory bowel disease in developing countries.","volume":"62","author":"Arebi","year":"2013","journal-title":"Gut."},{"key":"B12","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S2468-1253(16)30077-2","article-title":"Globalisation of inflammatory bowel disease: Perspectives from the evolution of inflammatory bowel disease in the UK and China.","volume":"1","author":"Kaplan","year":"2016","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/267630","article-title":"Trends and factors affecting hospitalization costs in patients with inflammatory bowel disease: A two-center study over the past decade.","volume":"2013","author":"Xu","year":"2013","journal-title":"Gastroenterol Res Pract."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1177\/17562848221102307","article-title":"The hospitalization burden of inflammatory bowel disease in China: A nationwide study from 2013 to 2018.","volume":"15","author":"He","year":"2022","journal-title":"Ther Adv Gastroenterol."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0153524","article-title":"Identification of environmental factors associated with inflammatory bowel disease in a Southwestern highland region of China: A nested case-control study.","volume":"11","author":"Niu","year":"2016","journal-title":"PLoS One."},{"key":"B16","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41395-018-0233-2","article-title":"Population density and risk of inflammatory bowel disease: A prospective population-based study in 13 countries or regions in Asia-Pacific.","volume":"114","author":"Ng","year":"2019","journal-title":"Am J Gastroenterol."},{"key":"B17","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1016\/j.cgh.2022.06.030","article-title":"Global hospitalization trends for Crohn\u2019s disease and ulcerative colitis in the 21st century: A systematic review with temporal analyses.","volume":"21","author":"Buie","year":"2023","journal-title":"Clin Gastroenterol Hepatol."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-023-02648-z","article-title":"The cost of illness analysis of inflammatory bowel disease.","volume":"23","author":"Pakdin","year":"2023","journal-title":"BMC Gastroenterol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ibd\/izz104","article-title":"The cost of inflammatory bowel disease: An initiative from the Crohn\u2019s & Colitis foundation.","volume":"26","author":"Park","year":"2020","journal-title":"Inflamm Bowel Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1093\/jcag\/gwy055","article-title":"The impact of inflammatory bowel disease in canada 2018: Direct costs and health services utilization.","author":"Kuenzig","year":"2019","journal-title":"J Can Assoc Gastroenterol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1053\/j.gastro.2013.07.041","article-title":"Risk of surgery for inflammatory Bowel diseases has decreased over time: A systematic review and meta-analysis of population-based studies.","volume":"145","author":"Frolkis","year":"2013","journal-title":"Gastroenterology."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1038\/ajg.2014.297","article-title":"Cumulative incidence of second intestinal resection in Crohn\u2019s disease: A systematic review and meta-analysis of population-based studies.","volume":"109","author":"Frolkis","year":"2014","journal-title":"Am J Gastroenterol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1053\/j.gastro.2011.10.001","article-title":"Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review.","volume":"142","author":"Molodecky","year":"2012","journal-title":"Gastroenterology."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1007\/s12325-020-01615-4","article-title":"Real-world prescription pattern and healthcare cost among patients with ulcerative colitis in Japan: A retrospective claims data analysis.","volume":"38","author":"Miyazaki","year":"2021","journal-title":"Adv Ther."},{"key":"B25","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1111\/apt.16444","article-title":"Comorbidity before and after a diagnosis of inflammatory bowel disease.","volume":"54","author":"Bernstein","year":"2021","journal-title":"Aliment Pharmacol Ther."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1038\/bjc.2017.127","article-title":"Comorbid conditions delay diagnosis of colorectal cancer: A cohort study using electronic primary care records.","volume":"116","author":"Mounce","year":"2017","journal-title":"Br J Cancer."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1007\/s00384-020-03716-6","article-title":"Anti-tumor necrosis factor therapy in patients with inflammatory bowel disease; comorbidity, not patient age, is a predictor of severe adverse events.","volume":"35","author":"Asscher","year":"2020","journal-title":"Int J Colorect Dis."},{"key":"B28","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1001\/archsurg.2011.194","article-title":"Risk of comorbidities on postoperative outcomes in patients with inflammatory bowel disease.","volume":"146","author":"Kaplan","year":"2011","journal-title":"Arch Surg."},{"key":"B29","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1002\/ibd.23026","article-title":"Older age is associated with higher rate of discontinuation of anti-TNF therapy in patients with inflammatory bowel disease.","volume":"19","author":"Desai","year":"2013","journal-title":"Inflamm Bowel Dis."},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0112479","article-title":"The Charlson comorbidity index can be used prospectively to identify patients who will incur high future costs.","volume":"9","author":"Charlson","year":"2014","journal-title":"PLoS One."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1016\/j.jpedsurg.2019.10.012","article-title":"Impact of nutritional deficiencies on children and young adults with Crohn\u2019s disease undergoing intraabdominal surgery.","volume":"55","author":"McLoughlin","year":"2020","journal-title":"J Pediatr Surg."},{"key":"B32","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1093\/ibd\/izx089","article-title":"Infections and cardiovascular complications are common causes for hospitalization in older patients with inflammatory Bowel diseases.","volume":"24","author":"Nguyen","year":"2018","journal-title":"Inflamm Bowel Dis."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1093\/ibd\/izaa310","article-title":"The impact of psychiatric comorbidity on health care utilization in inflammatory Bowel disease: A population-based study.","volume":"27","author":"Bernstein","year":"2021","journal-title":"Inflamm Bowel Dis."},{"key":"B34","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1097\/MEG.0000000000000891","article-title":"Chronic comorbidities associated with inflammatory bowel disease: Prevalence and impact on healthcare costs in Switzerland.","volume":"29","author":"B\u00e4hler","year":"2017","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.crohns.2010.09.008","article-title":"Increased risk for coronary heart disease, asthma, and connective tissue diseases in inflammatory bowel disease.","volume":"5","author":"Haapam\u00e4ki","year":"2011","journal-title":"J Crohns Colitis."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e189","DOI":"10.1097\/MCG.0000000000001647","article-title":"Polypharmacy in patients with inflammatory Bowel disease: Prevalence and outcomes in a single-center series.","volume":"56","author":"Mesonero","year":"2022","journal-title":"J Clin Gastroenterol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/apt.16454","article-title":"Longitudinal follow-up study: Effect of psychological co-morbidity on the prognosis of inflammatory bowel disease.","volume":"54","author":"Fairbrass","year":"2021","journal-title":"Aliment Pharmacol Ther."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1007\/s10620-020-06590-y","article-title":"Anemia severity associated with increased healthcare utilization and costs in inflammatory Bowel disease.","volume":"66","author":"Blaney","year":"2021","journal-title":"Dig Dis Sci."},{"key":"B39","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1177\/0272989X12437246","article-title":"Patient and other factors influencing the prescribing of cardiovascular prevention therapy in the general practice setting with and without nurse assessment.","volume":"32","author":"Mohammed","year":"2012","journal-title":"Med Decis Mak."},{"key":"B40","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1007\/s11606-011-1924-1","article-title":"Nurse-led disease management for hypertension control in a diverse urban community: A randomized trial.","volume":"27","author":"Hebert","year":"2012","journal-title":"J Gen Intern Med."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1410714\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T19:15:52Z","timestamp":1718133352000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1410714\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,7]]},"references-count":40,"alternative-id":["10.3389\/fmed.2024.1410714"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1410714","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,7]]},"article-number":"1410714"}}